Personalized Medicine: Pricing and Reimbursement Policies as a Potential Barrier to Development and Adoption, Economics of

Encyclopedia of Health Economics

Volumn , Issue , 2014, Pages 484-490

  Garrison, L P ^a   Towse, A ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Office of HealthEconomics   (United Kingdom)

Author keywords

Biomarker based test; Companion diagnostic; Cost effectiveness analysis; Cost utility analysis; Individualized therapy; Personalized medicine; Pharmacogenetics; Pricing; Reimbursement; Stratified medicine; Value capture; Value creation; Value based pricing

Indexed keywords

EID: 85009155288     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-375678-7.01210-4     Document Type: Chapter

References (14)

1. Danzon P., Towse A. The economics of gene therapy and of pharmacogenetics. Value Health 2002, 5(1):5-13.
2. Garrison L.P., Austin M.J.F. The economics of personalized medicine: A model of incentives for value creation and capture. Drug Information Journal 2007, 41:501-509.
3. Garrison, L. P., Veenstra, D. L., Carlson, R. J., Carlson, J. J. and Meckley, L. M. (2007). Backgrounder on pharmacogenomics for the pharmaceutical and biotechnology industries: Basic science, future scenarios, policy directions. Report of the Pharmaceutical Outcomes Research Policy and Program. Department of Pharmacy, University of Washington. Available at: (accessed 08.10.13). http://sop.washington.edu/porpp/general/reports.html.
4. Gustavsen G., Phillips K., Pothier K. The reimbursement landscape for novel diagnostics 2010, Health Advances, Weston, MA, Available at: http://www.healthadvances.com/pdf/novel_diag_reimbursement.pdf (accessed 08.10.13).
5. Wong W.B., Carlson J.J., Thariani R., Veenstra D.L. Cost effectiveness of pharmacogenomics: A critical and systematic review. Pharmacoeconomics 2010, 28(11):1001-1013.
6. Blair E.D., Stratton E.K., Kaufmann M. The economic value of companion diagnostics and stratified medicines. Expert Review of Molecular Diagnostics 2012, 12(8):791-794.
7. Davis J.C., Furstenthal L., Desai A.A., et al. The microeconomics of personalized medicine: Today's challenge and tomorrow's promise. Nature Reviews Drug Discovery 2009, 8(4):279-286.
8. Faulkner E., Annemans L., Garrison L., et al. Challenges in the development and reimbursement of personalized medicine - payer and manufacturer perspectives and implications for health economics and outcomes research: A report of the ISPOR Personalized Medicine Special Interest Group. Value Health 2012, 15(8):1162-1171. Personalized Medicine Development and Reimbursement Working Group.
9. Garrison L.P., Austin M.J.F. Linking pharmacogenetics-based diagnostics and pharmaceuticals for personalized medicine: Scientific and economic challenges. Health Affairs 2006, 25(5):1281-1290.
10. Keeling P., Roth M., Zietlow T. The economics of personalized medicine: Commercialization as a driver of return on investment. New Biotechnology 2012, 29(6):720-731.
11. Meckley L.M., Neumann P.J. Personalized medicine: Factors influencing reimbursement. Health Policy 2010, 94(2):91-100.
12. Ramsey S.D., Veenstra D.L., Garrison L.P., et al. Toward evidence-based assessment of laboratory-based diagnostics and genetic test for health plan reimbursement. American Journal of Managed Care 2006, 12:197-202.
13. Trusheim M.R., Berndt E.R., Douglas F.L. Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews Drug Discovery 2007, 6(4):287-293.
14. Veenstra D.L. The economic value of innovative treatments over the product life cycle: The case of targeted trastuzumab chemotherapy for breast cancer. Value in Health 2009, 12(8):1118-1123.